Morphocell Technologies is a regenerative medicine company focused on the development and commercialization of stem cell therapies and engineered tissues aimed at treating liver diseases.
Founded by clinicians and scientists to find new answers to compelling clinical needs affecting adult and children worldwide,
Morphocell Technologies aims at harnessing the power and promise of stem cells to develop new regenerative medicines. Through cutting-edge approaches of tissue engineering, Morphocell Technologies is developing revolutionary products targeting currently untreatable liver diseases. Its mission is to safely but promptly move such products from the laboratories to the clinical practice, where they can transform the treatment of liver disease.
Massimiliano Paganelli, MD, PhD
Pediatric transplant hepatologist, head of the Hepatology and Cell Therapy Lab at Sainte-Justine UHC, assistant professor of pediatrics at Université de Montréal, Max earned his medical degree at the Sapienza University of Rome, he trained in pediatrics in Rome and in pediatric hepatology and transplant in Naples and in Brussels. Max has a Ph.D. in Hepatology and Cell Therapy from the Catholic University of Louvain. Expert in cell therapy of liver diseases, he is a Stem Cell Network (“SCN”) investigator and a CIHR/FRQS-funded scientist. Driven by the needs of the young patients he takes care of, Max is seeking better ways to treat liver disease using novel stem cell therapies. With his team at Sainte-Justine UHC, he developed the Encapsulated Liver Tissue, on which Morphocell Technologies’ ReLiver™ technology is based.
Claudia Raggi, MD
Research associate in the Hepatology and Cell Therapy Lab and co-inventor of ReLiver™ technology with Dr. Paganelli, Claudia spearheads the stem cell biology, differentiation and cell manufacturing team at Morphocell. Educated in medicine at the University of Rome “La Sapienza” and at the Catholic University of Louvain, and a full-time basic and translational scientist since 2009, she is an expert in development and stem cell differentiation. Claudia and Max met as medical student in Rome and have been a partners in science as in life since they got married in 2006, sharing their passion for science and a mission to cure untreatable diseases. They are among a new generation of researchers pushing the boundaries of science by merging cutting-edge technologies such as stem cell biology, tissue engineering, biomaterials and genome editing with more traditional methods of enquiry.
Maggie Bywater Ekegärd, MD, M.Sc.
Educated in Pathology and Molecular Biology in Uppsala University, Sweden, Maggie is a senior executive with extensive experience in building biotechnology and life science-related businesses. Accomplished in identifying and commercializing technologies, as well as successfully bringing new classes of products to market in global biotech industry, she has extensive experience of start-up biotech companies and managing growth in small businesses, as well as in global organizations. A business developer and deal maker with over thirty years of industry experience in integration of technologies to answer difficult biological questions, she knows genomics, diagnostics, drug discovery and functional biology systems. Maggie has international experience in new product development for human health and agricultural biologicals markets. Maggie Bywater has spent her career in the business world identifying and establishing proprietary technologies; developing and manufacturing leading edge products; and developing markets to bring these products quickly to market. Maggie is passionate about the commercialization of novel technologies to advance the rapid application of research to society. She has never been afraid of a challenge, and enjoys patent and regulatory strategy.
Unlike current therapeutic strategies that mostly focus on treating symptoms and complications of a disease, regenerative medicine aims at replacing diseased cells, tissues and organs to restore lost functions and cure the disease.